Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReActiF-ICE: ARTICE Immune Cell Therapy in Septic Shock
NCT05442710Phase 2Recruiting
- Sponsor
- ARTCLINE GmbH
- Start
- Jul 2022
- Primary completion
- Mar 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of ARTICE in septic shock, sepsis, sponsored by ARTCLINE GmbH. Started Jul 2022; status: recruiting.
02
Drugs
ARTICE
03
Conditions
septic shocksepsis
Beyond the preview
Go deeper on NCT05442710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442710.